Table 7.

Clinical response in Phase 2

	Phase 2-Filanesib			Phase 2-Filanesib/Dex
	All Patients (N=31)	High AAG (N=6)	Low AAG (N=22)	All Patients (N=54)	High AAG (N=15)	Low AAG (N=35)
Best response, n (%)
Very good partial response	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Partial response	5 (16)	0 (0)	5 (23)	7 (13)	0 (0)	7 (20)
Minimal response	2 (6)	0 (0)	2 (9)	3 (6)	0 (0)	3 (9)
Stable disease	12 (39)	4 (67)	7 (32)	22 (41)	7 (47)	12 (34)
Progressive disease*	12 (39)	2 (33)	8 (36)	18 (33)	6 (40)	12 (34)
Not evaluable	0 (0)	0 (0)	0 (0)	3 (6)	2 (13)	1 (3)
Overall response rate (≥ PR)	5 (16)	0 (0)	5 (23)	8 (15)	0 (0)	7 (20)
Clinical benefit rate (≥ MR)	7 (23)	0 (0)	7 (32)	11 (20)	0 (0)	10 (29)

The “All Patients” columns use the response-evaluable population for each Phase 2 cohort; other columns use response-evaluable patients who had a baseline AAG value

^*Progressive disease may not have been confirmed.

High AAG = Baseline value > 110 mg/dL; Low AAG = Baseline value ≤ 110 mg/dL

Abbreviations: AAG = alpha 1-acid glycoprotein at baseline; Dex = dexamethasone; MR = minimal response; N or n = number; PR = partial response